血清WLA-Ag_1抗原水平在肺癌监测中的意义初探

用抗肺癌单克隆抗体WLA-2C_4、SABC-ELISA免疫结合抑制法,检测了100例正常人、93例肺癌患者和56例非肿瘤性疾病患者血清中WLA-Ag_1抗原水平。结果发现54％肺癌患者该抗原水平升高,其中与肺低分化腺癌(94％)呈现明显的相关性;而在健康成人和良性疾病患者,仅45％有该抗原水平升高。提示血清WLA-Ag_1抗原水平的升高可能有助干肺癌的临床监测。

Detection of a Circulating Antigen, WLA-Ag_1n Sera of Lung Carcinoma Patients by Monoclonal Antibody WLA-2C_4

WLA-Agl is an antigen defined by McAb WLA-2C4 to lung carcinoma, which is expressd predominantly in poorly to moderately-differentiated lung carcinoma, with molecular weight of 58 KD.The levels of WLA-Agl in sera from 100 healthy adults, 06 patients suffering from non-tumor diseases and 93 patients with lung carcinoma were measured semiquantitatively by the SABC-ELISA of immunobinding inhibition assay . Levels of antigen WLA-Agl exceeding the cut-off value (RBI = 12%) were found in 48% (15/31) squamous cell carcinoma, 55% (21/38) adeno-carcinoma, 57% (12/21) small cell carcinoma and all of the three large cell carcinoma, with the 54% (51/93) of tested lung carcinoma samples. It was also found that the positive percentage of WLA-Agl in sera from the patients with poorly-differentiated lung adenocarcinoma was 94% (16/17) , but only in 20% (2/10) of the tested bronchioloalveolar carcinoma and well-differentiated adenocarcinoma. The percentage of false positive from the sera of healthy adults and patients with the non-tumor disease was 4% (7/156). These results indicate that the WLA-Agl may be a valuble serological marker for the diagnosis of lung carcinoma.